Cannara Biotech (LOVE) Investor presentation summary

Strategic positioning and market leadership

• Ranked as a top-10 licensed producer in Canada, with #1 market share in Quebec and #8 nationally, operating three flagship brands and serving 94% of retail stores across 8 provinces.

• Achieved consecutive quarters of profitability, with 21 positive adjusted EBITDA quarters and 15 positive operating cash flow quarters.

• Expanded retail presence and product innovation have driven increased market share, especially in Ontario and Quebec.

Financial performance and growth

• Q3 2026 gross revenue reached $45.1M, up $6.3M year-over-year, with total revenue at $31.8M and gross profit before fair value adjustments at $13.4M.

• Adjusted EBITDA for Q3 2026 was $8.5M, with a margin of 27%, and net income was $4.8M.

• Operating cash flow for Q3 2026 was $5.7M, and free cash flow was $1.3M.

• As of May 31, 2026, cash stood at $21.8M, working capital at $65.1M, and total assets at $194.5M.

Operational scale and asset base

• Operates two mega facilities in Quebec: Valleyfield (1M sq. ft., 24 grow rooms, scalable to 100,000kg annualized output) and Farnham (605,000 sq. ft., 170,000 sq. ft. cannabis operations, R&D, and rental income from unoccupied space).

• 14 of 24 Valleyfield grow zones activated, supporting over 58,000kg annualized production; processing expansion on track to support 100,000kg by fiscal 2027.

• Disciplined, demand-led room activations and capital deployment target payback within 12 months, protecting margins and cash flow.